Nuveen
AVDL

Nuveen’s Avadel Pharmaceuticals AVDL Stock Holding History

Nuveen’s Portfolio AVDL Stock Details AVDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-607,268
Closed -$13.1M – 3233
2025
Q4 		$13.1M Buy
607,268
+92,975
+18% +$1.81M ﹤0.01% 1400
2025
Q3 		$7.85M Buy
514,293
+218,270
+74% +$2.84M ﹤0.01% 1685
2025
Q2 		$2.62M Sell
296,023
-221,916
-43% -$1.95M ﹤0.01% 2180
2025
Q1 		$4.06M Buy
517,939
+212,477
+70% +$1.78M ﹤0.01% 2026
2024
Q4 		$3.21M Buy
305,462
+54,773
+22% +$665K ﹤0.01% 2184
2024
Q3 		$3.29M Hold
250,689
– – ﹤0.01% 2189
2024
Q2 		$3.52M Buy
+250,689
New +$4.09M ﹤0.01% 2109

Other funds holding AVDL

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $20.6B AUM 34.61% 1-Year Est. Return

Nuveen's AVDL Position: Q1 2026 in Review

Nuveen sold out of Avadel Pharmaceuticals (AVDL) in Q1 2026, closing a stake of 607,268 shares — an estimated $13.1M sold.

Nuveen first reported a position in AVDL in Q2 2024 and held it in 7 quarters. The position peaked at $13.1M in Q4 2025. 2 funds tracked by Wall St. Rank hold AVDL as of Q1 2026.

  • Nuveen reported no remaining Avadel Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Nuveen sold 607,268 Avadel Pharmaceuticals shares in Q1 2026, an estimated $13.1M.
  • Nuveen first reported a position in Avadel Pharmaceuticals in Q2 2024 and held it in 7 quarters.
  • Nuveen's Avadel Pharmaceuticals position peaked at $13.1M in Q4 2025.
  • 2 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q1 2026.

Based on Nuveen's 13F filing for Q1 2026, filed 30 Apr 2026.